In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Juventas brings in $11.6mm through its Series B round; financing now at $22.2mm

Executive Summary

Cardiovascular drug developer Juventas Therapeutics Inc. (formerly AcelleRX Therapeutics) has raised $11.6mm through its Series B venture round. New Science Ventures led the financing and was joined by Takeda Ventures and undisclosed investors. The money will be used for two Phase II studies of JVS100--one to test for safety and effectiveness in heart failure patients, the other for critical limb ischemia.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies